INTRODUCTION
Coeliac disease is a common chronic inflammatory bowel condition encountered by doctors. Serological screening in healthy volunteers around the world has estimated the prevalence at 0.5-1.0%. [1] [2] [3] [4] [5] [6] [7] A recent metaanalysis indicated that the ratio of known to undiagnosed cases of coeliac disease was 1:7. 6 This suggests a failure in case finding for this disease. 6 8 9 The median age for diagnosis of coeliac disease in adults is between the fourth and fifth decade. [10] [11] [12] The median delay in diagnosis ranges from 4.9 to 11 years. [10] [11] [12] Patients with adult coeliac disease usually present with diarrhoea, weight loss, or symptoms that suggest malabsorption or anaemia. This type of coeliac disease is known as the classic (typical) form. The disease may not always be recognised however because of the insidious nature of its presentation, and many visits to hospital may be needed before diagnosis. 13 Patients can also have the silent or atypical form of disease. These patients may present with non-specific abdominal pain, 14 oesophageal reflux, 15 16 osteoporosis, cryptogenic hypertransaminasaemia, insulin dependent diabetes mellitus, 17 or neurological symptoms. 5 6 18 Untreated coeliac disease is associated with high morbidity and increased mortality. 19 20 Although the presentation of patients with coeliac disease may be protean, serological markers are a cheap and non-invasive method for clinicians in primary care and secondary care to identify patients with this disease. The positive and negative predictive value of combining the measurement of IgA antibodies to tissue transglutaminase and IgA endomysial antibodies has been reported to be greater than 96%. 21 Current serological testing for coeliac disease involves the use of one or both of these antibodies, depending on local practice. 22 However, the internationally accepted "gold standard" diagnostic test for coeliac disease is the demonstration of villous atrophy on a duodenal biopsy. 23 24 histologically according to the modified Marsh criteria and reflect the pathological progression (histologically) towards coeliac disease. Marsh grade 0 is normal duodenal mucosa, grade 1 is the presence of a raised intraepithelial lymphocyte count, and grade 2 is raised intraepithelial lymphocytes and crypt hyperplasia. Marsh grade 1 and grade 2 lesions are considered to be early changes in patients who are likely to develop coeliac disease. Marsh grade 3 is raised intraepithelial lymphocytes and crypt hyperplasia with progression of the inflammation to villous atrophy. Marsh grade 3 is subdivided into Marsh 3a-partial villous atrophy, 3b-subtotal villous atrophy, and 3c-total villous atrophy. 25 26 The presence of a Marsh 3 lesion (villous atrophy) on duodenal biopsy together with a positive antibody profile is currently internationally accepted as coeliac disease, although antibody negative coeliac disease does exist. 23 24 This may occur if patients are IgA deficient (and cannot generate IgA tissue transglutaminase antibodies or endomysial antibodies), but it can also happen in patients who have normal total IgA immunoglobulin concentrations. Such patients are classed as having coeliac disease if they have villous atrophy on duodenal biopsy and the appropriate human leucocyte antigen pattern (HLA DQ2 or HLA DQ8). They should also have symptoms suggestive of coeliac disease that respond to a gluten-free diet and show a corresponding improvement in histology. 23 24 A previous European multicentre series reported that antibody negative coeliac disease accounted for 6.4% (8 of 126) of all cases of coeliac disease. 27 A duodenal biopsy can be taken from any patient referred for gastroscopy. We and others have reported that 13.6% of patients later diagnosed with coeliac disease had had a gastroscopy within the previous five years but no duodenal biopsy had been taken. 10 This may be because of sole reliance on endoscopic features for recognising coeliac disease, even though such features are only 50-87.5% sensitive for detecting this disease. 28 Higher levels of detection are thought to correlate with endoscopic experience and the severity of villous atrophy. In addition, inter-rater reliability is poor. 28 Because of the limitations of endoscopy, antibody negative coeliac disease, and delays in diagnosis, many centres around the world suggest or recommend routine duodenal biopsy. In clinical practice, however, this policy varies greatly, and reported rates of duodenal biopsy range from 30.9% to 74%. [29] [30] [31] [32] The reported prevalence of coeliac disease when taking a routine duodenal biopsy ranges from 1.0% to 5.2%. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] However, prevalence depends greatly on the population studied. Since the advent of tissue transglutaminase and endomysial antibodies, the practice of routine duodenal biopsy has not been fully evaluated in the context of referrals from primary care.
We devised and evaluated a clinical decision tool that used a combination of pre-endoscopy serological testing (for tissue transglutaminase antibodies) and assessment of symptoms to identify patients with coeliac disease. This decision tool might help increase the detection of coeliac disease in patients attending for gastroscopy without the need to perform routine duodenal biopsy.
METHODS

Retrospective analysis and creation of a clinical decision tool
From January 2003 to January 2004 our centre performed 5979 gastroscopies. We analysed the data from 1464 unselected patients who had both a gastroscopy and duodenal biopsy. On the basis of this retrospective data, the prevalence of new cases of coeliac disease identified in patients referred for endoscopy was 4.2% (61 of 1464).
We assessed the indications for referral in these unselected patients and whether the biopsy findings indicated coeliac disease. We categorised patients with indications of weight loss, anaemia, or diarrhoea as having a "high risk" for coeliac disease. In routine clinical practice, such patients should have a duodenal biopsy taken as per British Society of Gastroenterology guidelines. 43 44 Anaemia was defined as a haemoglobin concentration of less than 120 g/l in female patients and less than 130 g/l in male patients; diarrhoea was defined as a bowel frequency of more than three times a day (both definitions as suggested by British Society of Gastroenterology guidelines). 43 44 Patients were deemed as having lost weight if this was stipulated in the referral letter from their general practitioner and confirmed by the patient at gastroscopy. The remaining patients (whose symptoms were atypical for coeliac disease) were categorised as having a "low risk." Symptoms classified as low risk include all other indications for gastroscopy, such as abdominal pain, reflux, dyspepsia, vomiting or nausea, and chest pain. Of the 1464 patients analysed who had gastroscopy and a duodenal biopsy, 1085 (74.1%) were high risk and 379 (25.9%) were low risk.
In this retrospective group, tissue transglutaminase antibody titre was part of the antibody profile performed in 109 patients. Eighty nine of the 109 patients (81.7%) were at high risk and 20 (18.3%) were at low risk of coeliac disease. Tissue transglutaminase antibody testing was performed in these patients because the investigating doctor considered coeliac disease to be a possible cause of their symptoms before gastroscopy. Eighteen of the 109 patients (16.5%) had coeliac disease, two of whom were negative for tissue transglutaminase antibodies. Nineteen of the 109 patients were positive for tissue transglutaminase antibodies-16 had coeliac disease but three had a normal duodenal biopsy. The sensitivity, specificity, positive predictive value, and negative predictive value for tissue transglutaminase antibodies in the detection of coeliac disease were 94.1%, 96.7%, 84.2%, and 97.8%. The two antibody negative patients with coeliac disease both had high risk referral symptoms. When we combined the referral indication of high risk with positive tissue transglutaminase antibody results the sensitivity for diagnosing coeliac disease was 100% (95% confidence interval 82.4% to 100%).
On the basis of these data, we devised a clinical decision tool that might obviate the need to perform routine duodenal biopsy but still detect unrecognised coeliac disease in patients referred for gastroscopy. We proposed that combining pre-endoscopy serological testing (using tissue transglutaminase antibodies) with identification of high risk patients would allow us to target patients who need a duodenal biopsy (fig 1) .
Prospective evaluation of clinical decision tool
We recruited patients from a single endoscopy department at the Royal Hallamshire Hospital, Sheffield. This centre serves a population of around 250 000 and carries out 5000-6000 gastroscopies annually. The patients had been referred by their general practitioner for either gastroscopy or a consultation and gastroscopy. A single endoscopist recruited participants for the evaluation study (second cohort) during a 26 month period (January 2004 to April 2006). The department of medical gastroenterology currently performs duodenal biopsy as part of the endoscopic examination. We classified all patients according to the referral information into high risk and low risk groups. At gastroscopy, we confirmed the symptoms described in the referral letter by questioning the patient directly and obtained patient consent. Quadrantic biopsies were taken from the second part of the duodenum in all patients. We also took a blood sample which was analysed for IgA tissue transglutaminase antibodies. We excluded patients if they had a known diagnosis of coeliac disease, coagulopathy (international normalised ratio >1.3 or platelets <80×10 9 /litre), or active gastrointestinal bleeding, or if a suspected carcinoma was identified during the examination (n=220).
Duodenal biopsy specimens were fixed in buffered formalin and embedded in paraffin wax. Standard 3 µm thick sections at three levels were stained with haematoxylin and eosin and reported routinely. We graded villous atrophy according to the modified Marsh criteria.
We used a commercially available enzyme linked immunosorbent assay to measure IgA antibodies to tissue transglutaminase. A titre of >15 U/ml was taken as positive (as recommended by the manufacturer).
We classed patients with villous atrophy and a negative antibody profile as having antibody negative coeliac disease only if they fulfilled previously described criteria. 23 24 45 46 To support such a diagnosis, we excluded alternative causes of villous atrophy (such as infection with Giardia or Helicobacter pylori) or selective IgA deficiency). In addition, all cases of coeliac disease and any equivocal cases were then reviewed by a gastrointestinal histopathologist who independently assessed the consistency of sampling and reporting.
Data analysis
We used SPSS version 10.0 to analyse the data; 95% confidence intervals were calculated by the Wilson method. We determined the sample size needed for our prospective study in consultation with the Sheffield University statistical services unit at the start of the study. For our prospective study to give a sensitivity of 100% (like our retrospective data), but with a narrower confidence width, our sample size needed to be 2000. This would give a 95% confidence interval of 98.8% to 100% (a width of 1.2%).
RESULTS
We recruited 2000 patients (1167 (58.3%) women, mean age 55.8, range . No patients refused to participate in the study. We categorised 739 patients into the high risk group and 1261 into the low risk group according to their referral indications (fig 2) . In total, 77 patients were newly diagnosed with coeliac disease. The independent gastrointestinal histopathology review confirmed consistency in both sampling and reporting of duodenal biopsies. No diagnoses were changed as a result of this review.
The prevalence of coeliac disease in all patients attending for gastroscopy was 3.9% (77/2000, 95% confidence interval 3.1% to 4.8%). In the high risk group prevalence was 9.6% (71/739, 7.7% to 12.0%).
The prevalence of tissue transglutaminase antibody negative coeliac disease was 0.4% (7/2000, 0.2% to 0.7%). All cases of antibody negative coeliac disease occurred in the high risk group (fig 2) . Only one of these seven antibody negative patients had selective IgA deficiency. Antibody negative coeliac disease accounted for 9.1% (7/77, 4.5% to 17.6%) of cases within this cohort.
The prevalence of coeliac disease in the low risk group was 0.5% (6/1261, 0.2% to 1.0%). Symptoms (abdominal pain, reflux, and irritable bowel syndrome) improved in these six patients when they ate a gluten-free diet (duration of follow-up three to 18 months).
Using the tissue transglutaminase antibody test alone to diagnose coeliac disease gave a sensitivity, specificity, positive predictive value, and negative predictive value of 90.9%, 90.9%, 28.6%, and 99.6%. 
RESEARCH
Evaluating the clinical decision tool Combining biopsy of the high risk group and those patients with a positive antibody result gave a sensitivity of 100% (77/77, 95.2% to 100%). The specificity was 60.8% (1170/1923, 58.6% to 63.0%), positive predictive value was 9.3% (77/830, 7.5% to 11.4%), and negative predictive value was 100% (1170/1170, 99.7% to 100%) (fig 2) . The prevalence of coeliac disease in patients undergoing biopsy as a result of the decision tool was 9.3%.
DISCUSSION
Previous investigators have suggested clinical algorithms for diagnosing coeliac disease. 29 47 We devised and evaluated a strategy of pre-endoscopy serological testing for coeliac disease combined with biopsy of high risk cases. The clinical decision tool had a sensitivity of 100% (95.2% to 100%) in our cohort of patients and no cases of coeliac disease were missed. Although the decision tool was accurate, the confidence interval was around 5%, so this tool may not necessarily detect all cases when applied to other groups.
Limitations
We performed the serological testing in secondary care on patients from primary care. We did not test the implementation of this decision tool in primary care. The prevalence of coeliac disease is lower in primary care (0.5-1.0% [1] [2] [3] [4] [5] [6] [7] ) than in the endoscopy unit (1.0-5.2% [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , and this might affect the performance of the decision tool.
Implications By using our clinical decision tool instead of routine duodenal biopsy, 58.5% (1170/2000) of patients would have avoided a duodenal biopsy yet the same number of cases of coeliac disease would have been detected.
Our data support the need for duodenal biopsy in high risk patients even if they are antibody negative. 43 44 Given this observation, one option would be to serologically test the low risk group only. However, the definitions of high risk and low risk are based on current British Society of Gastroenterology guidelines, which are probably not widely available in primary care. We therefore think the most pragmatic approach would be serological testing for all patients referred for gastroscopy.
The exact antibody test needed is debateable. Many centres recommend a two step approach (tissue transglutaminase antibodies first, followed by endomysial antibodies in patients with positive results). 47 However, for logistical reasons this approach may not be applicable to pre-endoscopy testing-the complete antibody profile may not be available by the time the patient arrives for gastroscopy. We found that using tissue transglutaminase antibodies alone was adequate and cheap and that no cases of coeliac disease were overlooked. Testing for tissue transglutaminase antibodies is the cheapest and most accurate option, as the immunofluorescence method used to detect endomysial antibodies is subjective and uses expensive tissue as the substrate (monkey oesophagus or umbilical cord). 47 The advent of point of care testing for tissue transglutaminase antibodies may influence clinical practice. 48 49 Preliminary reports suggest that sensitivity and specificity are comparable to those seen for serology. 48 49 Point of care testing might shift the onus to conduct this test from general practitioners to the endoscopy unit, where the test could perhaps be done immediately before endoscopy. This might be a more effective way of using the decision tool in the future. However, in the United Kingdom because of practice based commissioning (for primary care), many general practitioners may choose to adopt this policy as a cost effective approach.
Cost effectiveness
We anticipate that our decision tool will be cost effective. In our study, the decision tool reduced the workload associated with processing and reporting duodenal biopsies to 41.5% of that of the routine biopsy method. Earlier diagnosis might result in fewer consultations in primary care and possibly fewer referrals to secondary care, 13 which would also reduce healthcare costs. In addition, a prompt diagnosis would improve the quality of life for patients with coeliac disease at an earlier stage and potentially save money by delaying onset of the complications of coeliac disease.
Conclusion
In this data set, pre-endoscopy serological testing combined with biopsy of high risk cases had a sensitivity of 100%. The use of this clinical decision tool may enable the endoscopist to target patients who need a duodenal biopsy. This strategy might increase the detection rate of coeliac disease.
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